Remove Compounding Remove Immunization Remove Magazine
article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors.